Insta
Covax Initiative Asks WHO To Expedite Emergency Use Listing Of Bharat Biotech's Covaxin
Swarajya Staff
May 25, 2021, 09:41 AM | Updated 09:41 AM IST
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
The international COVID-19 vaccine sharing initiative called Covax has asked the World Health Organisation (WHO) to expedite the approval for Hyderabad-based Bharat Biotech’s Covaxin which is the first indigenously developed Indian vaccine against COVID-19, reports Economic Times.
In a meeting held on Friday (21 May), Covax facility experts from India and other nations recommended the approval of Covaxin and Russia's Sputnik V. This gains significance as WHO’s approval is a prerequisite for any COVID-19 vaccine to be included under the Covax for distribution.
It should be noted that so far, the WHO has only given approvals to the vaccines from Europe and North America.
Also, in a meeting yesterday (24 May), External Affairs Secretary Harsh Vardhan Shringla is said to have assured Bharat Biotech of the “fullest support” of diplomatic establishment in securing the approvals from the WHO and important countries.
Dr Krishna Ella led company had submitted its expression of interest for an emergency use listing (EUL) of Covaxin to WHO in April. Following this, the WHO had asked Bharat Biotech for additional details. The company is expected to submit its final dossier of details soon.
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
Introducing ElectionsHQ + 50 Ground Reports Project
The 2024 elections might seem easy to guess, but there are some important questions that shouldn't be missed.
Do freebies still sway voters? Do people prioritise infrastructure when voting? How will Punjab vote?
The answers to these questions provide great insights into where we, as a country, are headed in the years to come.
Swarajya is starting a project with an aim to do 50 solid ground stories and a smart commentary service on WhatsApp, a one-of-a-kind. We'd love your support during this election season.
Click below to contribute.